DON AGRO INTERNATIONAL LIMITED

Registration No. 201835258H
(Incorporated in the Republic of Singapore)

1) MONTHLY VALUATION OF ASSETS AND UTILISATION OF CASH FOR THE MONTH OF MAY 2025; AND

2) UPDATE OF MILESTONES IN OBTAINING NEW BUSINESS

The Board of Directors (the "**Board**" or the "**Directors**") of Don Agro International Limited (the "**Company"**) refers to the announcement released on the SGXNet on 8 July 2024 notifying shareholders of its cash company status pursuant to Rule 1017(1)(a) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist (the "**Catalist Rules**") and its previous announcement dated 30 May 2025 on the monthly updates.

Pursuant to Catalist Rule 1017(1)(b), the Board wishes to announce the following:

1. MONTHLY VALUATION OF ASSETS AND UTILISATION OF CASH FOR THE MONTH OF MAY 2025

a) The Company's assets and liabilities as at 31 May 2025 were as follows:

	$'000
Assets	
Long-term investment	530
Trade and other receivables	44,477
Cash and cash equivalents	25,895
Total assets	70,902
Liabilities	
Trade and other payables	1,254
Current tax liabilities	88
Provisions	620
Total liabilities	1,962
Net assets	68,940

(b) The Company's utilisation of cash from 1 May 2025 to 31 May 2025 was as follows:

	RR'000[1 & 2]	**$'000**
Opening cash and bank balances as at 1 May 2025	1,835,184	29,326
Add receipts:		
Interest income from deposit	788	13
Government grants	-	2
Foreign currency translation adjustment	-	1,032
Total receipts	788	1,047
Less payments**:**		
Loan to Target Company	(236,000)	(3,784)
Bank charges and miscellaneous	(49)	(1)

[1] Relates to Russian subsidiaries of the Company and does not relate to the Company

[2] RR 62.64 to $ 1 as at 1 May 2025; RR 62.37 to $ 1 for May 2025; RR 60.17 to $ 1 as at 31 May 2025.

General and administrative expenses	(43,203)	(693)
Total payments	(279,252)	(4,478)
Closing cash and bank balances as at 31 May 2025	**1,556,720**	**25,895**

All figures set out in this announcement have not been reviewed or audited by the Company's auditors.

2. UPDATE OF MILESTONES IN OBTAINING A NEW BUSINESS

As mentioned in the announcement dated 12 September 2024 in relation to the proposed acquisition of 812 Capital LLC and Centre for Innovative Medical Technologies, LLC (the "**Proposed Acquisition Announcement**"), that JSC Tetra, a wholly-owned subsidiary of the Company had, on 6 September 2024, entered into the agreements in respect of the proposed acquisition of 99.99% of the shares in 812 Capital LLC and 11.50% of the shares in Centre for Innovative Medical Technologies, LLC (together with their respective subsidiaries, the "**Target Group**").

The Target Group is a Russian network of expert oncology clinics operating under the "Euroonco" brand that provide a full range of cancer diagnostics and treatment. Entities operating under the Euroonco brand, focus primarily on providing a full range of cancer diagnostics and treatment services, as well as all types of antitumor and palliative treatment. Euroonco has expert oncology clinics and information and service centres in Moscow, Saint Petersburg and Krasnodar. Please refer to the Proposed Acquisition Announcement for further details.

As announced on 21 January 2025, the Company had on 17 January 2025 received a letter from SGX-ST informing that SGX-ST has no objections to the, Cash Utilisation Waiver, Escrow Requirement Waiver and Continued Trading Application (the "**Waiver and Application Confirmation**") (the "**Waiver Announcement**") subject to the satisfaction of certain conditions (the "**Conditions**"). Please refer to the Waiver Announcement for further details.

As announced on 27 February 2025, the Group has fulfilled the Conditions as stated in the Waiver and Application Confirmation. For details, please refer to announcement dated 27 February 2025 for further details.

In March 2025, the Consideration Advance Payments and payment of the CIMT Stake Consideration (as defined in the Proposed Acquisition Announcement) of RR 2,220,000,000 for the proposed acquisition of medical business (equivalent to approximately S$34,495,000)[3] were remitted to the Vendors (as defined in the Proposed Acquisition Announcement) after obtaining the Waiver and Application Confirmation from SGX-ST on 17 January 2025 as mentioned above.

As announced on 1 June 2025, the Company received the letter from the SGX advising that SGX-ST has no objections to the Company's application for a waiver from the requirement to disclose the pro forma financial statements of the enlarged group (the "**Pro Forma Waiver Announcement**"). The waiver is subject to the satisfaction of certain conditions. Please refer to the Pro Forma Waiver Announcement for further details.

The Company's auditors and legal advisors are continuing audit and due diligence for the proposed acquisition of 812 Capital LLC and Centre for Innovative Medical Technologies, LLC. They are also preparing a circular, which will be disseminated to the Company's shareholders in due course, in accordance with SGX-ST requirements before the extraordinary general meeting to be convened.

In May 2025 JSC Tetra extended a short-term loan amounted to RR 236,000,000 or approximately $3,8 million (the "**Loan**") to the Target Group in order to provide funding for an acquisition of groups of companies which operates polyclinic in Moscow under Uni Clinica brand, acquisition of which allows the Target Group to expand its medical facilities significantly. For avoidance of doubt, the Loan provided is

[3] Based on the average exchange rate of S$1.00 = RR 64.36 for March 2025

not part of the Company's Escrowed Amount.

On 17 June 2025 the Company submitted an application to the Singapore Exchange Securities Trading Limited through PrimePartners Corporate Finance Pte. Ltd., for a six month extension for the Company to meet the requirements for a new listing pursuant to Rule 1017(2) of the Catalist Rules (the "**Extension Application**"). The Company shall update the shareholders in relation to the outcome of the Extension Application accordingly.

BY ORDER OF THE BOARD

Marat Devlet-Kildeyev
Chief Executive Officer and Executive Director
1 July 2025

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.